A novel pathologic marker, indoleamine 2,3-dioxygenase 1, for the cholangiopathy of immune checkpoint inhibitors-induced immune mediated hepatotoxicity as adverse events and the prediction of additional ursodeoxycholic acid treatment
Kaori Yoshimura, Yuko Tamano, Hiep Nguyen Canh, Li Zihan, Dong Le Thanh, Yasunori Sato, Takeshi Terashima, Shinji Shimoda, Kenichi Harada
Topics & Concepts
Indoleamine 2,3-dioxygenaseUrsodeoxycholic acidAutoimmune hepatitisMedicineImmune systemPrimary sclerosing cholangitisHepatitisInternal medicineGastroenterologyImmunologyBiologyDiseaseAmino acidBiochemistryTryptophanCancer Immunotherapy and BiomarkersLiver Diseases and ImmunityImmune Cell Function and Interaction